RNAi

Entity type image
Type: Keyphrase
Name: RNAi
First reported 2 hours ago - Updated 2 hours ago - 1 reports
Life Technologies Corp
Life Technologies Corp

Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China

Invivofectamine® Rx-formulated therapeutic is 100-fold more potent than previous in-vivo transfection products from LifeCARLSBAD, Calif., June 19, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announces a licensing agreement ... [Published Michigan Live - 2 hours ago]
First reported 4 hours ago - Updated 3 hours ago - 2 reports
OTC Markets Group Inc
OTC Markets Group Inc

RXi Pharmaceuticals Corporation Begins Trading on OTCQX®

/PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing, and ... [Published Michigan Live - 3 hours ago]
First reported Jun 18 2013 - Updated Jun 18 2013 - 1 reports

Expression and role of PGP, BCRP, MRP1 and MRP3 in multidrug resistance of canine mammary cancer cells

In both women and female dogs, the most prevalent type of malignant neoplasm is the spontaneous mammary tumor. In dogs, half of these are malignant. The treatment of choice for the canine patients is surgical mastectomy. Unfortunately, it often fails ... [Published BMC - Jun 18 2013]
First reported Jun 17 2013 - Updated Jun 17 2013 - 1 reports

Characterization of PUD-1 and PUD-2, Two Proteins Up-Regulated in a Long-Lived daf-2 Mutant

by Yue-He Ding, Yun-Guang Du, Shukun Luo, Yu-Xin Li, Tie-Mei Li, Sawako Yoshina, Xing Wang, Karsten Klage, Shohei Mitani, Keqiong Ye, Meng-Qiu DongC. elegans PUD-1 and PUD-2, two proteins up-regulated in daf-2(loss-of-function) (PUD), are homologous 17-kD ... [Published Elites TV - Jun 17 2013]
First reported Jun 16 2013 - Updated Jun 16 2013 - 2 reports

Gene tech safe FSANZ

FOOD Standards Australia New Zealand (FSANZ) has responded to claims in a scientific journal article that risk assessments of ribonucleic acid interference (RNAi) technology - a form of gene silencing used in plant breeding - were insufficient, by saying ... [Published The Sydney News - Jun 16 2013]
First reported Jun 13 2013 - Updated Jun 13 2013 - 2 reports
Dendreon Corp
Dendreon Corp

For Love and Money: Three Growth Stocks from Casey's Alex Daley

(Investorideas.com Newswire) Alex Daley, senior editor of Casey Extraordinary Technology, seeks out undiscovered names because that's where he finds the big upside. In this interview with , Daley brings his best ideas to investors who won't shy away from ... [Published InvestorIdeas.com - Jun 13 2013]
First reported Jun 13 2013 - Updated Jun 13 2013 - 1 reports

Arrowhead to Present at Upcoming Scientific Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that the company will present data on the Dynamic PolyConjugate™ (DPC) siRNA delivery system and the ARC-520 hepatitis B drug candidate at three upcoming scientific ... [Published Reuters - Jun 13 2013]
First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

Extraordinary researcher honoured

This year’s Rössler Prize has been awarded to Olivier Voinnet, Professor of RNA Biology in the Department of Biology, ETH Zurich. The Frenchman receives the CHF 200,000 research prize for his groundbreaking discoveries in the field of molecular and cell ... [Published ETH Life - Jun 12 2013]
Entities: RNAi, ETH Zürich, RNA
First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

Alnylam Pharma Coverage Initiated by Analysts at Morgan Stanley (ALNY)

Equities researchers at Morgan Stanley began coverage on shares of Alnylam Pharma (NASDAQ: ALNY) in a research report issued on Tuesday, Stock Ratings Network.com reports. The firm set an “overweight” rating and a $35.00 price target on the stock. Morgan ... [Published The Utah People's Post - Jun 12 2013]
First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

Juvenile Hormone and Insulin Regulate Trehalose Homeostasis in the Red Flour Beetle, Tribolium castaneum

Insulin/IGF-1 signaling (IIS) has been well studied for its role in the control of life span extension and resistance to a variety of stresses. The Drosophila melanogaster insulin-like receptor (InR) mutant showed extended life span due to reduced juvenile ... [Published Bionity.com - Jun 12 2013]
First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

RSR-2, the Caenorhabditis elegans Ortholog of Human Spliceosomal Component SRm300/SRRM2, Regulates Development by Influencing the Transcriptional Machinery

by Laura Fontrodona, Montserrat Porta-de-la-Riva, Tomás Morán, Wei Niu, Mònica Díaz, David Aristizábal-Corrales, Alberto Villanueva, Simó Schwartz, Valerie Reinke, Julián CerónProtein components of the spliceosome are highly conserved in eukaryotes and ... [Published Bionity.com - Jun 12 2013]
First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

Learning gene network structure from time laps cell imaging in RNAi Knock downs

Motivation: As RNA interference is becoming a standard method for targeted gene perturbation, computational approaches to reverse engineer parts of biological networks based on measurable effects of RNAi become increasingly relevant. The vast majority ... [Published Bionity.com - Jun 12 2013]

Quotes

...in the world to advance siRNA technology," said Alan Sachs, M D , Ph D , chief scientific officer and head of global research at Life Technologies. "In our continued effort to deliver game-changing products and technologies to the world's top medical researchers, we are pleased to partner with Dr. Liang and Suzhou Ribo Life Sciences. Invivofectamine Rx is a great example of the type of technology we will continue to license around the world as we expand our commitment to clinical research customers."
Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siR ... [Published Michigan Live - 2 hours ago]
...Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. "With OTCQX, we can clearly convey our qualifications to the financial markets and ensure our shareholders receive high-quality disclosure, transparent trading and easy access through their regulated U S broker-dealer."
RXi Pharmaceuticals Corporation Begins Trading on OTCQX® [Published Michigan Live - 3 hours ago]
...Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. "This accomplishment marks another milestone for RXi as we continue to develop our self-delivering RNAi-based (sd-rxRNA(R)) technology platform into commercially viable assets."
RXi Pharmaceuticals (RXII) Shares to Begin Trading on OTCQX® [Published 4 Traders - 4 hours ago]
...increasingly used for the sequence-specific inhibition of gene expression by the cleavage of mRNAs encoding proteins of interest [Welch et al., "Expression of ribozymes in gene transfertransfer systems to modulate target RNA levels." Curr Opin Biotechnol. 1998 October; 9(5):486-96]...
Long lasting drug formulations [Published PharmCast - 14 hours ago]

More Content

All (299) | News (184) | Reports (10) | Blogs (25) | Audio/Video (0) | Fact Sheets (3) | Press Releases (77)
sort by: Date | Relevance
Life Technologies Signs Licensing Agreement wit... [Published Michigan Live - 2 hours ago]
RXi Pharmaceuticals Corporation Begins Trading ... [Published Michigan Live - 3 hours ago]
RXi Pharmaceuticals (RXII) Shares to Begin Trad... [Published 4 Traders - 4 hours ago]
ATR Inhibition Broadly Sensitizes Ovarian Cance... [Published Bionity.com - 6 hours ago]
A boost to higher education [Published Times Union - 7 hours ago]
Long lasting drug formulations [Published PharmCast - 14 hours ago]
Compositions and methods for silencing genes in... [Published PharmCast - 14 hours ago]
American Vanguard Should Reap A Better Multiple [Published Seeking Alpha - 18 hours ago]
Drug Delivery in Central Nervous System Disease... [Published Individual.com - 23 hours ago]
Silence Therapeutics : Atu027 update: progressi... [Published Investegate - Jun 18 2013]
Expression and role of PGP, BCRP, MRP1 and MRP3... [Published BMC - Jun 18 2013]
Gene Therapy - Technologies, Markets and Compan... [Published TickerTech.com - Jun 17 2013]
Characterization of PUD-1 and PUD-2, Two Protei... [Published Elites TV - Jun 17 2013]
More bad science in the service of anti-GMO act... [Published Science-Based Medicine - Jun 17 2013]
Gene tech safe FSANZ [Published The Sydney News - Jun 16 2013]
Gene tech 'safe': FSANZ [Published Stock & Land - Jun 16 2013]
2 Biotechs With Recent Intensive Insider Selling [Published Seeking Alpha - Jun 16 2013]
New Findings from Netherlands Cancer Institute ... [Published NewsRX - Jun 16 2013]
Role of the Aryl Hydrocarbon Receptor in Carcin... [Published Toxicological Sciences - Jun 15 2013]
Once You Start Up Financings of the Fortnight, ... [Published The IN VIVO Blog - Jun 14 2013]
Scientists at UMass Medical School identify neu... [Published EurekAlert! - Jun 14 2013]
OMICS Group Incorporation Acquires Journal of M... [Published PR.com Press Releases - Jun 14 2013]
miRagen Therapeutics Strengthens Its Senior Man... [Published Individual.com - Jun 14 2013]
Monsanto hopes to win over beekeepers with cure [Published STLtoday.com - Jun 14 2013]
Alnylam Pharmaceuticals' Management Presents at... [Published Seeking Alpha - Jun 14 2013]
For Love and Money: Three Growth Stocks from Ca... [Published InvestorIdeas.com - Jun 13 2013]
Arrowhead to Present at Upcoming Scientific Con... [Published Reuters - Jun 13 2013]
For Love and Money: Three Growth Stocks from Ca... [Published Trefis - Jun 13 2013]
OMICS GROUP announces acquisition of Journal of... [Published Online PR News - Jun 13 2013]
Extraordinary researcher honoured [Published ETH Life - Jun 12 2013]
1 2 3 4 5 6 7 8 9 10
In Focus
  •  
Craig Mello, Joseph Payne, Geert Cauwenbergh, [more]
  •  
Alnylam Pharmaceuticals Inc, RXi Pharmaceuticals Corp, Opko Health Inc, [more]
  •  
University of California San Diego, United States Patent And Trademark Office, Public Library of Science, [more]
  •  
Therapeutics, sirna, RNA Interference, [more]
  •  
OTCQX, Kynamro, VaxiRNA, [more]
  •  
San Diego (California, United States), Dublin, Mount Sinai (United States), [more]
  •  
United States, Japan, Canada, [more]
  •  
Medicine, Biotechnology, Biology, [more]
  •  
Pharma & Biotech, Health, Banking & Financial Services, [more]
Business Wire Health News, EON Health & Medicine, PharmaBiz, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
More bad science in the service of anti-GMO act... [Published Science-Based Medicine - Jun 17 2013]
I never used to write much about genetically modified organisms (GMOs) before. I still don’t do it that often. For whatever reason, it just hasn’t been on my radar very much. That seems to be changing, however. It’s not because I went seeking this issue ...
Once You Start Up Financings of the Fortnight, ... [Published The IN VIVO Blog - Jun 14 2013]
Your faithful FOTF correspondent is in San Diego this week for the CalBIO conference, specifically to wax journalistic on a panel trying to look into the future – 2030! -- and opine sagely upon what we see. Some call this prediction; others call this ...
Natural GMOs Part 167. The fight against genome... [Published GMO Pundit a.k.a. David Tribe - Jun 05 2013]
June 04, 2013In the gonads of animals, genome parasites such as transposons pose a serious threat to evolutionary fitness. With their ability to bounce around in the genome, they often cause dangerous mutations. To protect genomic integrity, animals evolved ...
This Week in PLOS [Published The Daily Scan from GenomeWeb - Jun 03 2013]
In PLOS this week: microRNA repression of Twist1, effect of cool temperatures on RNAi machinery in mosquitoes, and more. read more ...
Arcturus Therapeutics Raises $1.3 Million in Se... [Published Pharma-Mag - Jun 03 2013]
Financing from High Net-Worth Private Investors to Fuel RNAi Delivery Technologies for the Treatment of Disease Arcturus Therapeutics Inc. announced it has raised $1.3 million in a seed funding round led by multiple high net-worth private investors from ...
1 2 3 4 5

Press Releases

sort by: Date | Relevance
OMICS Group Incorporation Acquires Journal of M... [Published PR.com Press Releases - Jun 14 2013]
Alnylam to Webcast Presentation at Goldman Sach... [Published Business Wire Health News - Jun 06 2013]
EGEN, Inc. Advances a Systemically Delivered R... [Published PR Newswire - Jun 05 2013]
Arcturus Therapeutics Raises $1.3 Million in Se... [Published PR Newswire: Financial Services - Jun 03 2013]
Arrowhead Files to Begin Phase 1 Trial of RNAi ... [Published Business Wire Health News - May 28 2013]
1 2 3 4 5 6 7 8 9 10 ...
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.